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Edited by Richard MaraisAbstract We found that zaprinast, a well-known cyclic guano-
sine monophosphate-speciﬁc phosphodiesterase inhibitor, acted
as an agonist for a G protein-coupled receptor, GPR35. In our
intracellular calcium mobilization assay, zaprinast activated
rat GPR35 strongly (geometric mean EC50 value of 16 nM),
whereas it activated human GPR35 moderately (geometric mean
EC50 value of 840 nM). We also demonstrated that GPR35
acted as a Gai/o- and Ga16-coupled receptor for zaprinast when
heterologously expressed in human embryonic kidney 293
(HEK 293) cells. These ﬁndings will facilitate the research on
GPR35 and the drug discovery of the GPR35 modulators.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The G protein-coupled receptors (GPCRs) are a large family
of cell surface receptors that account for over 30% of current
drug targets [1]. Sequencing of the human genome has led to
the discovery of novel GPCRs, and many of them are orphan
receptors for which the natural ligands have not yet been iden-
tiﬁed. To determine the biological functions of these orphan
GPCRs, identiﬁcation of their natural ligands is the ﬁrst step.
However, despite extensive attempts at receptor–ligand pair-
ing, a number of GPCRs are still orphan receptors. GPR35
[2] is one of these orphan GPCRs. It shares homology with
some of the purinergic receptors [2], GPR23/P2Y9 (the recep-
tor for lysophosphatidic acid) [3], and HM74 (the receptor for
nicotinic acid) [4]. Although chromosomal mapping and the
expression of GPR35 in a number of human tissues have been
investigated in previous studies [2,5,6], little is known about
this receptor.Abbreviations: GPCR, G protein-coupled receptor; PDE, phosphodi-
esterase; HEK293, human embryonic kidney 293; hGPR35, human
GPR35; FLAG-hGPR35, FLAG-tagged human GPR35; rGPR35, rat
GPR35; DRG, dorsal root ganglion; cGMP, cyclic guanosine mono-
phosphate
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doi:10.1016/j.febslet.2006.08.015Here we report that zaprinast [7], a well-known cGMP spe-
ciﬁc-phosphodiesterases (cGMP-PDEs) inhibitor [8], acts as an
agonist for GPR35. The cyclic nucleotide phosphodiesterases
are a large group of structurally-related enzymes [9,10].
Among them, PDE4, PDE7, and PDE8 are speciﬁc enzymes
for cyclic adenosine monophosphate (cAMP), whereas
PDE5, PDE6, PDE9 are speciﬁc enzymes for cyclic guanosine
monophosphate [9,10]. Other PDEs have dual activities [9,10].
They diﬀer in their mode of action, intracellular distribution,
tissue distribution, relative activities, and Km values [9,10].
Various stimuli induce cellular responses by increasing the
intracellular levels of cAMP and cGMP, and PDEs account
for degradation of these intracellular second messengers to ter-
minate the signals and the cellular responses [9,10]. Therefore,
regulation of PDEs activities is important to control the intra-
cellular second messenger levels and physiological responses,
and speciﬁc PDE inhibitors are utilized as both research tools
and remedies [10]. For example, sildenaﬁl (Viagra) is a po-
tent selective PDE5 inhibitor and an orally active drug for
erectile dysfunction [7]. Zaprinast, a lead compound for silde-
naﬁl, is known as a moderate inhibitor for cGMP-PDEs, espe-
cially PDE5 and PDE6 (IC50 values for PDE5, PDE6, PDE9
are 0.5–076, 0.15, and 35 lM) [7,11]. Zaprinast also inhibits
PDE10, and PDE11 weakly (IC50 values are 22 and 11–
33 lM, respectively) [11]. By using an intracellular calcium
mobilization assay, we show that zaprinast activates GPR35-
G protein pathways and this activity of zaprinast in this assay
is not attributable to inhibition of PDEs. We have also found
that GPR35 acts as a Gai/o- and Ga16-coupled receptor for
zaprinast when heterologously expressed in human embryonic
kidney 293 (HEK293) cells.2. Materials and methods
2.1. Chemicals
Zaprinast, 8-bromoguanosine 3 0,5 0-cyclic monophosphate (8Bromo-
cGMP), T-0156 and T-1032 were purchased from Sigma.
2.2. Cloning of rat GPR35 (rGPR35)
To generate cDNA templates for RT-PCR, 5 lg of total RNA from
rat colon (Clontech) was reverse-transcribed by using SUPERSCRIPT
Preampliﬁcation Systems (Invitrogen), and an aliquot (1 lL) of the
products was subjected to PCR. To amplify rGPR35, two primers
(5 0-TCCGTCAGATGAGCCCTAGGACC-30 and 5 0-CACAGGTTC
CTCTGGCCCTTGGCATG-3 0) were designed on the basis of the
nucleotide sequence of mouse GPR35 (GenBank Accession No.
BC027429), and PCR was performed under the following conditions:
94C for 4 min followed by 35 cycles of 94 C for 20 s, 50 C forblished by Elsevier B.V. All rights reserved.
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the PCR products were separated by electrophoresis. Although some
non-speciﬁc ampliﬁcation was observed, a product of the expected size
(900–1000 bp) was obtained. The fragment was gel-puriﬁed and TA-
cloned using TOPO TA Cloning Kit (Invitrogen). Then several of
the clones obtained were sequenced. Three independent experiments
were performed to determine the sequence of rGPR35 gene without
PCR errors (GenBank Accession No. AB240684).
2.3. Expression vectors
The original cDNA for human GPR35 (hGPR35) was isolated from
human dorsal root ganglion (DRG) cDNA library (Life Technologies)
using GENETRAPPER III cDNA Positive Selection System (Life
Technologies) and an oligonucleotide probe (5 0-ATG GTNYAYA
TGCCNGGNGAYG-30). Compared with the published sequence of
hGPR35 (GenBank Accession No. AF027957), the hGPR35 obtained
in this study had three non-synonymous single nucleotide polymor-
phisms (T108M, R174A, and R294S). Among them, T108M and
R294S have been reported previously [5], while R174A was registered
in the NCBI human genome database. The fragment for FLAG-tagged
human GPR35 (FLAG-hGPR35) was generated by using the follow-A
B
C
Fig. 1. Discovery of zaprinast as an agonist for hGPR35. (A) Expression of
HEK293 cells transiently coexpressing the receptor (FLAG-hGPR35 or wil
loaded with Fura-2, and then were exposed to zaprinast (broken line; addition
for FLAG-hGPR35 and wild-type hGPR35 were 5.2 and 1.9 lM, respectively
in HEK293 cells. The Fura-2-loaded HEK293 cells transiently coexpressin
exposed to zaprinast (broken line; addition of zaprinast).ing pair of primers: 5 0-CCGGAATTCGCCACCATGGATTAC-
AAGGATGACGACGATAAGAATGGCACCTACAACACCTG-3 0
and 5 0-TCGTCTAGAATTAGGCGAGGGTCACGCACA-3 0. All of
cDNAs used in this study were subcloned into pcDNA3.1 (Invitrogen).
2.4. Cell transfection and calcium mobilization assay
Transfection of HEK293 cells was performed by using FuGENE 6
Transfection Reagent (Roche) according to the manufacturer’s instruc-
tions. In brief, 400000 cells were transfected with 40 lg of the expres-
sion vectors using 60 lL of FuGENE 6 Transfection Reagent. Two
days after transfection, the cells were washed twice with Hanks’ bal-
anced salt solution (HBSS) without CaCl2 or MgCl2 (Gibco) and
loaded with 5 lM Fura 2-AM (Dojindo) in HBSS containing 0.05%
Pluronic F-127 (Sigma) for 1 h at 37 C. After the incubation, the cells
were harvested by centrifugation and diluted to 1–3 · 105 cells/mL in
HBSS containing CaCl2, MgCl2, and MgSO4 (Gibco). Then aliquots
of the cell suspension (90 lL) were dispensed into 96-well plates (Cos-
ter). Addition of 10 lL of each ligand solution and measurement of
intracellular calcium mobilization were performed with FDSS6000
(Hamamatsu Photonics). Concentration–response curves were deter-
mined using GraphPad Prism 3 (GraphPad Software).FLAG-hGPR35 in HEK293 cells conﬁrmed by Western blotting. (B)
d-type hGPR35) and/or Ga proteins (Gqs5,Gqi5,Gqo5, and Ga16) were
of zaprinast). Dose–response curves are shown in parallel. EC50 values
. (C) GPR35 acted as a Gai/o- and Ga16-coupled receptor for zaprinast
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Fig. 3. Eﬀect of zaprinast on rat GPR35. Fura-2-loaded HEK293 cells
transiently coexpressing rat or human GPR35 and Gqi5 were exposed
to zaprinast and intracellular calcium mobilization was measured.
Concentration–response curves are from three independents experi-
ments with each point determined in quadruplicate.
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To conﬁrm the expression of FLAG-hGPR35, 1.5 · 106 cells were
dissolved in 150 lL of Tris–SDS–BME sample loading buﬀer (Owl)
and analyzed by Western blotting. An aliquot (20 lL) of each sample
was separated by SDS–PAGE and blotted onto polyvinylidene diﬂuo-
ride membranes. After blocking with TBS buﬀer containing 1.2%
bovine serum albumin, the blot was probed with anti-FLAG M2
monoclonal antibody (Sigma) and the anti-mouse secondary antibody
(Immunotech). The signal was visualized by using ECL Western blot-
ting detection reagents (Amersham). The size of FLAG-hGPR35 ob-
served in this study was about 31 kDa (Fig. 1A).
2.6. Tissue distribution of rGPR35
After euthanasia, DRG and spinal cord tissues were removed from a
10-week-old pregnant female Sprague–Dawley rat, and treated with
ISOGEN (Toyobo) to purify total RNAs (all animal experiments per-
formed in this study were approved by the Animal Ethics Committee
of the Nagoya Laboratories of Pﬁzer Japan, based on the internal
guidelines for animal experiments and adherence to Pﬁzer policy).
Total RNAs from other tissues were purchased from BD Clontech
or Unitech. To generate cDNA templates for RT-PCR, total RNA
(5 lg) was reverse-transcribed by using SUPERSCRIPT Preampliﬁca-
tion Systems. To assess possible contamination by genomic DNA, a
series of samples without reverse transcriptase (RT) were prepared
in parallel as negative controls. Then 1 lL of each reverse-transcribed
sample was used as a template for subsequent PCR. PCR was per-
formed to amplify rGPR35 using two primers (5 0-AAATTGTAG-
CATCCTCCCGTGGCC-3 0 and 5 0-TATCTTGGCTCTTGTGGGG-
TGTGC-3 0) under the following condition: 94 C for 4 min followed
by 35 cycles of 94 C for 20 s, 58 C for 30 s, and 72 C for 1 min,
and ﬁnally 72 C for 4 min. As a positive control, glyceraldehyde-3-A
B
rat GPR35 (+ RT)
rat GPR35 (- RT)
rat GAPDH
10
0 
bp
 D
NA
 L
ad
de
r
br
a
in
ce
re
be
llu
m
ce
re
br
u
m
sk
e
le
ta
l m
u
sc
le
u
te
ru
s
he
ar
t
Fig. 2. Cloning and tissue distribution of rGPR35. (A) Alignment of the dedu
distribution of rGPR35 (expected size; 887 bp) determined by semi-quantitati
reverse transcriptase was performed in parallel. GAPDH (expected size; 245phosphate dehydrogenase (GAPDH) was also ampliﬁed by the same
PCR procedure (except that 30 cycles were performed) using the
following primers: 5 0-GTCTTCACCACCATGGAGAAGGCT-3 0
and 5 0-GTGATGGCATGGACTGTGGTCATGA-30. After PCR,lu
ng
liv
e
r
bl
ad
de
r
st
om
ac
h
sm
a
ll 
in
te
st
in
e
co
lo
n
10
0 
bp
 D
NA
 L
ad
de
r
do
rs
al
 ro
ot
 g
an
gl
io
n
sp
in
al
 c
or
d
ced amino acid sequences of human, mouse, and rat GPR35. (B) Tissue
ve RT-PCR (+RT). As a negative control (RT), RT-PCR without the
bp) was also ampliﬁed in parallel as a positive control (rat GAPDH).
5006 Y. Taniguchi et al. / FEBS Letters 580 (2006) 5003–5008the samples were separated by electrophoresis and DNA was visualized
by ethidium bromide staining. The PCR products were conﬁrmed by
sequencing.3. Results
3.1. Identiﬁcation of zaprinast as an agonist for hGPR35
To discover ligands for GPR35, we prepared HEK293 cells
transiently coexpressing FLAG-hGPR35, three chimeric Ga
proteins (Gqs5, Gqi5, and Gqo5) [12], and promiscuous Ga16
[12], because the downstream signaling molecules of GPR35
were unknown at that time. The chimeric Ga proteins and
Ga16 are used to redirect Gas- and/or Gai/o-mediated signals
to the Gaq signaling pathway, thus allowing evaluation of
the activity of most GPCRs by a calcium mobilization assay
using the above-mentioned G proteins [12]. After cells werehuman GPrat GPR35 + Gqi5
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Fig. 4. Eﬀects of selective PDE5/PDE6 inhibitors (T-0156 and T-1032) and 8B
cells expressing GPR35 and Gqi5. (A) Structures of assayed compounds. F
HEK293 cells transiently coexpressing rat or human GPR35 and Gqi5 were ex
zaprinast (10 lM).loaded with Fura-2, about 1000 compounds were assayed by
using the FDSS6000 to monitor intracellular calcium mobiliza-
tion. Among them, zaprinast (a well-known PDEs inhibitor)
induced intracellular calcium mobilization in HEK293 cells
coexpressing FLAG-hGPR35 and the four exogenous G pro-
teins (Fig. 1B), while there was little change of calcium in
the control transfectant only expressing the chimeric Ga pro-
teins and Ga16 (Fig. 1B). Further analysis showed that zapri-
nast induced intracellular calcium mobilization in the
transfectant coexpressing FLAG-hGPR35 and the four exoge-
nous Ga proteins in a concentration-dependent manner
(Fig. 1B). A similar result was obtained in an experiment using
wild-type hGPR35 (Fig. 1B). These results suggest that zapri-
nast is an agonist for hGPR35.
Next, we examined which of the Ga proteins was involved in
mediation of the signaling. When FLAG-hGPR35 was co-
expressed in HEK293 cells with Gqi5, Gqo5, or Ga16, zaprinastR35 + Gqi5 Gqi5 only
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no response to zaprinast was observed in either cells expressing
Gqs5 and FLAG-hGPR35 or cells expressing FLAG-hGPR35
alone (Fig. 1C). These results show that hGPR35 functions
as a Gai/o- and Ga16-coupled receptor for zaprinast in
HEK293 cells.3.2. Cloning and tissue distribution of rGPR35
Next, we have cloned rGPR35 to evaluate the eﬀect of zapri-
nast on this receptor. To identify and isolate rGPR35 cDNA
clone, we designed a pair of primers based on the sequence
of mouse GPR35, and the entire ORF of rGPR35 was ampli-
ﬁed by RT-PCR using these primers. Then the PCR product of
the expected size was TA-cloned and sequenced. The PCR
product contained a 921-bp ORF of rGPR35 (data not
shown). The amino acid sequence of the cloned rGPR35
showed 72% and 85% identity with human and mouse
GPR35, respectively (Fig. 2A). We also investigated tissue dis-
tribution of rGPR35 by semi-quantitative RT-PCR (Fig. 2B).
Consistent with previous studies preformed in human [5,6], we
detected expression of rGPR35 in lung, stomach, small intes-
tine, colon, and skeletal muscle. In addition, a relatively high
level of expression in uterus and DRG, as well as moderate
expression in brain, cerebrum, heart, liver, bladder, and spinal
cord, was shown in this study (Fig. 2B).3.3. Zaprinast as a potent agonist for rGPR35
To conﬁrm that zaprinast was an agonist for rGPR35,
HEK293 cells transiently coexpressing rat or human GPR35
and Gqi5 were prepared, and the transfectants were exposed
to zaprinast (Fig. 3). In this assay, zaprinast caused the mod-
erate activation of hGPR35 (geometric mean EC50 value of
840 nM), while zaprinast had a potent eﬀect on the transfec-
tant co-expressing rGPR35 and Gqi5 (geometric mean EC50 va-
lue of 16 nM). These results suggest that the zaprinast is able
to act as a potent agonist for rGPR35.3.4. PDE5/PDE6 inhibitors without GPR35 agonist activity
To further support our ﬁndings in this study, we evaluated
the eﬀect of phosphodiesterase inhibitors of a diﬀerent chemi-
cal class on HEK293 cells transiently coexpressing either rat or
human GPR35 and Gqi5. T-0156 and T-1032 are known as po-
tent PDE5 inhibitors (IC50 values are 0.23 and 1 nM, respec-
tively) [11,13,14] and also inhibit PDE6 (IC50 values are 56
and 28 nM, respectively) [11,13,14]. T-0156 and T-1032 are
structurally diﬀerent from zaprinast, a cGMP analog
(Fig. 4A) [13,14]. As shown in Fig. 4B, T-0156 (10lM) and
T-1032 (10 lM) did not induce substantial intracellular cal-
cium mobilization in HEK293 cells transiently coexpressing
either rat or human GPR35 and Gqi5, although zaprinast did
so. These results indicate that T-0156 and T-1032 do not act
as GPR35 agonists, and support our conclusion that the eﬀect
of zaprinast on intracellular calcium mobilization is attribut-
able to its agonist activity for GPR35, not to inhibitory activity
for PDE5/PDE6. In addition, we also conﬁrmed that 8-bro-
moguanosine 3 0,5 0-cyclic monophosphate (8Bromo-cGMP), a
membrane-permeable analogue of cGMP, did not induce the
intracellular calcium mobilization in these transfectants
(Fig. 4B), suggesting that elevation of intracellular cGMP level
was unlikely to be responsible for the intracellular calcium
mobilization in this assay system.4. Discussion
In this study, we demonstrated that zaprinast (a cGMP-PDE
inhibitor) induced the intracellular calcium mobilization in the
cells coexpressing GPR35 and Gqi5, Gqo5, or Ga16. Induction of
intracellular calcium mobilization by zaprinast in the GPR35-
expressing transfectants was due to selective activation of the
GPR35-Ga (Gqi5, Gqo5, or Ga16) signaling pathway, rather
than inhibition of phosphodiesterases (PDE5, PDE6, PDE9,
PDE10, and PDE11), direct activation of Ga proteins, or
non-selective stimulation of endogenous GPCR-Ga signaling
pathway, because expression of both GPR35 and Ga proteins
(Gqi5, Gqo5, or Ga16) was necessary preconditions for this ac-
tion of zaprinast (Figs. 1B, C, and 3). Thus, these observations
strongly suggest that zaprinast acts as an agonist for GPR35.
Zaprinast potently induced intracellular calcium mobilization
in the transfectant coexpressing rGPR35 and Gqi5 with an
EC50 value of 16 nM (Fig. 3), while eﬀects of zaprinast on
PDEs are moderate or weak (see Section 1). In addition, the
selective PDE5/PDE6 inhibitors T-0156 and T-1032 did not
have any eﬀect on the transfectants coexpressing GPR35 and
Gqi5 (Fig. 4B). Furthermore, 8Bromo-cGMP did not induce
intracellular calcium mobilization in our assay (Fig. 4B). These
facts also support our conclusion.
Several recent reports have suggested that zaprinast may
possess pharmacological activities other than PDEs inhibition.
For example, Wibberley et al. demonstrated a nitric oxide
(NO)-independent role for zaprinast in the regulation of ure-
thral sphincter tone [15]. Yoon et al. reported that intrathecal
zaprinast had an antinociceptive eﬀect in the rat formalin test,
and that this eﬀect was not related to the NO-cGMP-potas-
sium channel pathway [16]. Because cGMP PDEs are deeply
involved in the NO-cGMP signaling pathway (NO activates
soluble guanylyl cyclase to increase the intracellular cGMP le-
vel, while cGMP PDE terminates NO/cGMP-dependent sig-
nals by degrading cGMP) [17], these NO/cGMP-independent
eﬀects of zaprinast may be mediated by GPR35 activation.
Numerous reports about pharmacological studies of PDEs
inhibition by zaprinast have been published [7]. However, it
may be necessary to repeat those experiments with diﬀerent
structural classes of selective PDE inhibitors since the
GPR35 agonist activity of zaprinast was revealed in this study.
It is important to note that zaprinast is a lead compound for
sildenaﬁl (Viagra) [7], indicating that zaprinast has favorable
chemical properties for drug design. It may be feasible to iden-
tify potent and selective agonists and/or antagonists for
hGPR35 without phosphodiesterase inhibitory activity from
among compounds related to zaprinast. In fact, we have al-
ready identiﬁed a number of GPR35 agonists with diﬀerent po-
tency and species selectivity among zaprinast derivatives
(Taniguchi et al, Patent Application WO2005085867(A2)),
suggesting that zaprinast may serve as a lead compound to de-
velop drugs that modulate GPR35 activity.
During the review process of this manuscript, Wang et al.
reported that kynurenic acid was a natural ligand for
GPR35 [18]. They independently showed that GPR35 acted
as a Gai/o- and Ga16-coupled receptor using kynurenic acid,
which was consistent with our results obtained with zaprinast.
However, aﬃnity of kynurenic acid for GPR35 is relatively low
(EC50 values of 7.4–39.2 lM) [18]. Thus, other chemical
classes of natural ligand with higher aﬃnity may be expected.
Because GPR35 shares homology with GPCRs belonging to
5008 Y. Taniguchi et al. / FEBS Letters 580 (2006) 5003–5008the P2Y family [2] and zaprinast is a xanthine derivative [7],
our ﬁndings may provide a hint to discover the natural ligand
for GPR35.
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